AP
PETX

AlpInvest Partners’s Aratana Therapeutics, Inc. PETX Stock Holding History

AlpInvest Partners’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100,001
Closed -$632K – 25
2016
Q2 		$632K Hold
100,001
– – 1.25% 17
2016
Q1 		$552K Hold
100,001
– – 1.05% 22
2015
Q4 		$558K Hold
100,001
– – 0.93% 20
2015
Q3 		$846K Buy
+100,001
New +$1.69M 1.67% 15

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AlpInvest Partners's PETX Position: Q3 2016 in Review

AlpInvest Partners sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2016, closing a stake of 100,001 shares — an estimated $632K sold.

AlpInvest Partners first reported a position in PETX in Q3 2015 and held it in 4 quarters. The position peaked at $846K in Q3 2015. 128 funds tracked by Wall St. Rank hold PETX as of Q3 2016.

  • AlpInvest Partners reported no remaining Aratana Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • AlpInvest Partners sold 100,001 Aratana Therapeutics, Inc. shares in Q3 2016, an estimated $632K.
  • AlpInvest Partners first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
  • AlpInvest Partners's Aratana Therapeutics, Inc. position peaked at $846K in Q3 2015.
  • 128 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2016.

Based on AlpInvest Partners's 13F filing for Q3 2016, filed 14 Nov 2016.